Well, I guess I am out?

[Anonymous]

Hilarious about the Fanapt reps. They actually hired some reps that sold Fanapt. Although I can't remember even a handful of scripts in my territory. Wow. Top of the bunch reps.

Don't forget Saphris reps too What a blockbuster.

 

[Anonymous]

I know of a number of LAT candidates that either stepped away after panels or just declined offers. If they get approval, it will take 4-5 years for this drug to hit forecast. Who is going to stick around? Better yet, will executive management trust the commercial operation to launch other drugs.

I know several of the target speakers that have already turned them down. I think that says engouh there.

In 4-5 years I plan on being well into the launch of an MDD med and olanzapine(without weight gain) med. you on the other hand will be begging for another shot to work here. At least you Sunovion reps will be full of memories of Gish performing cover songs at National sales meetings while wondering WTF just happened.

 

[Anonymous]

In 4-5 years I plan on being well into the launch of an MDD med and olanzapine(without weight gain) med. you on the other hand will be begging for another shot to work here. At least you Sunovion reps will be full of memories of Gish performing cover songs at National sales meetings while wondering WTF just happened.

Engouh said, you have no idea how this industry and drugs get developed. Alk just now is starting the phase 3, which means at a min you have 18-24 months of study. Add another 10-12 months on the review plus 6 months min to prepare the application, you get 3 years at the earliest and luckiest. However if you follow FDA and this portion of the industry, it will be more like 4 years.

Finally, if you had any MD connections what so ever in this field. They would honestly tell you that olan and metaformin will do the same thing. In this cost adverse market, you will have no one cover the drug. The MDD drug might get some staying power, but the future of that market is going to saturated with new brands and generics, ECT.

Good luck to all who took the offers, keep your resume polished.

 

[Anonymous]

Engouh said, you have no idea how this industry and drugs get developed. Alk just now is starting the phase 3, which means at a min you have 18-24 months of study. Add another 10-12 months on the review plus 6 months min to prepare the application, you get 3 years at the earliest and luckiest. However if you follow FDA and this portion of the industry, it will be more like 4 years.

Finally, if you had any MD connections what so ever in this field. They would honestly tell you that olan and metaformin will do the same thing. In this cost adverse market, you will have no one cover the drug. The MDD drug might get some staying power, but the future of that market is going to saturated with new brands and generics, ECT.

Good luck to all who took the offers, keep your resume polished.

Says the guy who can't stay off the Alkermes message board on a weekend. Obsessed much?

 

[Anonymous]

Engouh said, you have no idea how this industry and drugs get developed. Alk just now is starting the phase 3, which means at a min you have 18-24 months of study. Add another 10-12 months on the review plus 6 months min to prepare the application, you get 3 years at the earliest and luckiest. However if you follow FDA and this portion of the industry, it will be more like 4 years.

Finally, if you had any MD connections what so ever in this field. They would honestly tell you that olan and metaformin will do the same thing. In this cost adverse market, you will have no one cover the drug. The MDD drug might get some staying power, but the future of that market is going to saturated with new brands and generics, ECT.

Good luck to all who took the offers, keep your resume polished.

I've read that the MDD drug received FDA fast track designation, and has completed 1 of 3 p3 studies with great results. Used in adjunctive therapy with those not getting adequate response to SRI or SNRI. Good efficacy as early as week 1. Very tolerable SE profile. Final p3 studies soon completed this year with NDA filing late 2015/ early 2016. Good timing 1.5 years after LAT launch. Seems promising to me, but with people like you who seem to know it all with sweeping generalizations about the FDA process what do I know.

 

[Anonymous]

I've read that the MDD drug received FDA fast track designation, and has completed 1 of 3 p3 studies with great results. Used in adjunctive therapy with those not getting adequate response to SRI or SNRI. Good efficacy as early as week 1. Very tolerable SE profile. Final p3 studies soon completed this year with NDA filing late 2015/ early 2016. Good timing 1.5 years after LAT launch. Seems promising to me, but with people like you who seem to know it all with sweeping generalizations about the FDA process what do I know.

You're right about everything you state except that the trials won't be completed until mid-2016, so back your time line up a year to 2017-18. Still promising for many with MDD that aren't getting relief from current therapies.

 

[Anonymous]

I've read that the MDD drug received FDA fast track designation, and has completed 1 of 3 p3 studies with great results. Used in adjunctive therapy with those not getting adequate response to SRI or SNRI. Good efficacy as early as week 1. Very tolerable SE profile. Final p3 studies soon completed this year with NDA filing late 2015/ early 2016. Good timing 1.5 years after LAT launch. Seems promising to me, but with people like you who seem to know it all with sweeping generalizations about the FDA process what do I know.

Do you even know what "Fast Track" means? It is a company request that FDA can grant for a number of things.

You still have 1.5 years till that drug is to market from now, if lucky! 6 more months of writing studies/filling out the 100k pages and questions FDA requires, and 10 months of FDA review. Good luck selling an opioid drug in pysch.

 

[Anonymous]

Do you even know what "Fast Track" means? It is a company request that FDA can grant for a number of things.

You still have 1.5 years till that drug is to market from now, if lucky! 6 more months of writing studies/filling out the 100k pages and questions FDA requires, and 10 months of FDA review. Good luck selling an opioid drug in pysch.

Sounds like wishful thinking troll boy. The FDA always fast tracks meds that don't show promise and nobody wants. Glad you didn't make the cut. Good luck selling Latuda, I really mean it. We don't compete and you have 2 short years left to sell it before the massive downsizing begins.Hope that helps!

 

[Anonymous]

I'm so proud that some of you are able to identify the posters! guess what? That's the point! Alkermes will more than likely get bought out by big pharma. It's the board's decision when they can cash in

 

[Anonymous]

Mr otsuka please tell me when your option vest at otsuka? oh wait...
Mr otsuka tell me what your quarter target payout is? I think its a pharma type payout
Mr otsuka are you getting in trouble for your call average? 8 per day please

Sayonara!